- ►diabetesjournals.org NN Rudovich, HJ Rochlitz, AFH Pfeiffer - Diabetes, 2004 - Am Diabetes Assoc Our objective was to study whether young first-degree relatives of patients with
type 2 diabetes (FDRs) have altered insulin secretion and insulin clearance in
response to gastric inhibitory polypeptide (GIP) in combination with ... Cited by 29 - Related articles - BL Direct - All 4 versions
N Irwin, BD Green, VA Gault, B Greer, P … - Journal of Medicinal Chemistry, 2005 - diabetica.co.uk Exploitation of glucose-dependent insulinotropic polypeptide (GIP) is hindered
by its short biological half-life and rapid renal clearance. To circumvent these
problems, two novel acylated N-terminally modified GIP analogues, N-pGluGIP( ... Cited by 15 - Related articles - View as HTML - All 8 versions
- ►qub.ac.uk [PDF] BD Green, PR Flatt, CJ Bailey - Expert Opin. Emerging Drugs, 2006 - informahealthcare.com Dipeptidyl peptidase IV (DPP IV) is a ubiquitous, multifunctional, serine
protease enzyme and receptor with roles in the control of endocrine and immune
function, cell metabolism, growth and adhesion. As an enzyme, DPP IV ... Cited by 17 - Related articles - BL Direct - All 6 versions
- ►diabetica.co.uk [PDF] N Irwin, VA Gault, BD Green, B Greer, P … - Biological chemistry, 2005 - reference-global.com Fatty acid derivatisation was used to develop two novel, long-acting,
N-terminally modified, glucose-dependent insulinotropic polypeptide (GIP)
analogues, N-Ac- GIP(LysPAL16) and N-AcGIP(LysPAL37). In contrast to GIP, ... Cited by 17 - Related articles - BL Direct - All 10 versions
JJ Meier, B Gallwitz, B Kask, CF Deacon, JJ … - Diabetes, 2004 - Am Diabetes Assoc A reduced insulinotropic effect of gastric inhibitory polypeptide (GIP) is a
characteristic of patients with type 2 diabetes. It was the aim of this study to
determine the response of insulin secretion to different GIP doses ... Cited by 41 - Related articles - BL Direct - All 4 versions
- ►qub.ac.uk [PDF] N Irwin, GC Clarke, BD Green, B Greer, P … - Biochemical pharmacology, 2006 - Elsevier Glucose dependent insulinotropic polypeptide (GIP) is a gastrointestinal hormone
with therapeutic potential for type 2 diabetes due to its insulin-releasing and
antihyperglycaemic actions. However, development of GIP-based therapies is ... Cited by 11 - Related articles - All 5 versions
JJ Meier, MA Nauck, N Siepmann, M Greulich, … - Metabolism, 2003 - Elsevier Insulin secretion following the intravenous infusion of gastric inhibitory
polypeptide (GIP) is diminished in patients with type 2 diabetes and at least a
subgroup of their first-degree relatives at hyperglycemic clamp conditions. ... Cited by 20 - Related articles - All 12 versions
AI Salhanick, KB Clairmont, TM Buckholz, CM … - Bioorganic & medicinal chemistry letters, 2005 - Elsevier The effects of PEGylation of glucose-dependent insulinotropic polypeptide (GIP)
on potency and dipeptidyl peptidase IV (DPPIV) stability are reported.
N-terminal modification of GIP(1–30) with 40 kDa polyethylene glycol ... Cited by 12 - Related articles - All 5 versions
- ►endojournals.org H Kindmark, J Pigon, S Efendic - Journal of Clinical Endocrinology & Metabolism, 2001 - Endocrine Soc Glucose-dependent insulinotropic hormone (GIP) is an intestinal hormone
considered to be an important mediator of the incretin effect, ie the augmented
insulin release observed in response to orally, compared with iv, ... Cited by 12 - Related articles - BL Direct - All 4 versions
- ►physiology.org CF Deacon, A Plamboeck, MM Rosenkilde, J … - American Journal of Physiology- Endocrinology And …, 2006 - Am Physiological Soc Glucose-dependent insulinotropic polypeptide [GIP-(1–42)] is degraded by
dipeptidyl peptidase IV (DPP IV), forming GIP-(3–42). In mice, high
concentrations of synthetic GIP-(3–42) may function as a GIP receptor ... Cited by 12 - Related articles - BL Direct - All 3 versions
